Chemotyping of yeast mutants using robotics

• Published in: Yeast (Chichester, England) England), 1999-07, Vol.15 (10B), p.973-986
• Main Authors: Rieger, Klaus‐Jörg, El‐Alama, Mohamed, Stein, Georg, Bradshaw, Charles, Slonimski, Piotr P., Maundrell, Kinsey
• Format: Article
• Language: English
• Subjects: Antifungal Agents - pharmacology; Culture Media; Drug Resistance, Microbial; drug‐sensitivity/resistance; functional analysis; genome; Genome, Fungal; Microbial Sensitivity Tests; Mutation; Phenotype; Robotics; Saccharomyces - classification; Saccharomyces - drug effects; Saccharomyces - genetics; Saccharomyces - physiology; Saccharomyces cerevisiae
• ISSN: 0749-503X; 1097-0061
• DOI: 10.1002/(SICI)1097-0061(199907)15:10B<973::AID-YEA402>3.0.CO;2-L

By now, the EUROFAN programme for the functional analysis of genes from the yeast genome has attained its cruising speed. Indeed, several hundreds of yeast mutants with no phenotype as tested by growth on standard media and no significant sequence similarity to proteins of known function are available through the efforts of various laboratories. Based on the methodology initiated during the pilot project on yeast chromosome III (Yeast 13, 1547–1562, 1997) we adapted it to High Throughput Screening (HTS), using robotics. The first 100 different gene deletions from EUROSCARF, constructed in an FY1679 strain background, were run against a collection of about 300 inhibitors. Many of these inhibitors have not been reported until now to interfere in vivo with growth of Saccharomyces cerevisiae. In the present paper we provide a list of novel growth conditions and a compilation of 49 yeast deletants (from chromosomes II, IV, VII, X, XIV, XV) corresponding to 58% of the analysed genes, with at least one clear and stringent phenotype. The majority of these deletants are sensitive to one or two compounds (monotropic phenotype) while a distinct subclass of deletants displays a hyper‐pleiotropic phenotype with sensitivities to a dozen or more compounds. Therefore, chemotyping of unknown genes with a large spectrum of drugs opens new vistas for a more in‐depth functional analysis and a more precise definition of molecular targets. Copyright © 1999 John Wiley & Sons, Ltd.